

CITATION REPORT

List of articles citing

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.

DOI: 10.1021/acs.jcim.1c01451

Journal of Chemical Information and Modeling, 2022, , .

Source: <https://exaly.com/paper-pdf/125239226/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
357	Searching for escape-resistant anti-SARS-CoV-2 neutralizing antibodies.. 2022,		0
356	Discriminatory Weight of SNPs in Spike SARS-CoV-2 Variants: A Technically Rapid, Unambiguous, and Bioinformatically Validated Laboratory Approach.. 2022, 14,		
355	Omicron variant in the current SARS-CoV-2 pandemic.. 2022,		3
354	The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?. 2022, 1		8
353	Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response.. 2022, 102527		0
352	Prion-like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2.. 2022, 10,		3
351	Guidelines, Recommendations and Consensus on Obstructive Sleep Apnea.. 2022, 58, 3-4		1
350	South Africa's COVID-19 vaccine rollout amid the emergence of Omicron. 2022, 4, 1-2		0
349	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants.. 2021, 8, 836826		0
348	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.. 2022, 10,		4
347	Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?. 2022, 158, 78-81		10
346	Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.. <i>Journal of Chemical Information and Modeling,</i> 2022,	6.1	116
345	Rapid and Accurate Identification of SARS-CoV-2 Omicron Variants Using Droplet Digital PCR (RT-ddPCR).		2
344	Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveler returning from overseas.. 2022, 1-9		3
343	Quantifying transmission risk of SARS-CoV-2 in different situations.. 2022, 376, o106		0
342	Structural insight into antibody evasion of SARS-CoV-2 omicron variant.		
341	The Impact of Accumulated Mutations in SARS-CoV-2 Variants on the qPCR Detection Efficiency.. 2022, 12, 823306		3

340	The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials.. 2022,	10
339	Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.. 2022,	7
338	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.. 2022,	102
337	Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery.. 2022,	6
336	Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2.. 2022, 28, e936199	1
335	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.. 2022, 209, 112816	27
334	COMMENTARYOmicron (B.1.1.529) variant of SARS-CoV-2- Concerns, challenges and recent updates.. 2022,	26
333	Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children?. 2022,	1
332	Natural products as a source of novel drugs for treating SARS-CoV2 infection.. 2022, 12, 1-1	3
331	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. 2022, 58,	0
330	Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study.. 2022, 165, 184-194	7
329	The rise and fall of SARS-CoV-2 variants and the emergence of competing Omicron lineages.	3
328	Data-Driven Multiscale Modelling and Analysis of COVID-19 Spatiotemporal Evolution Using Explainable AI.. 2022, 103772	2
327	Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.. 2022,	14
326	A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.. 2022, 243, 38-38	6
325	South African Population Immunity and Severe Covid-19 with Omicron Variant.	14
324	Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults.	3
323	SARS-CoV-2 Omicron variant: exploring healthcare workers' awareness and perception of vaccine effectiveness: a national survey during the first week of WHO variant alert.	0

322	Update on omicron variant: What we know so far.. 2022 , 54, 41-45	0
321	Augmenting the public health response to ensure effective containment of the Omicron variant. 2022 , 7, 12	
320	Detección del primer caso de COVID-19 relacionado a la variante Omicron en México. 2022 , 20, 62-66	
319	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. 2022 , 11,	4
318	Omicron booster in ancestral strain vaccinated mice augments protective immunities against both the Delta and Omicron variants.	0
317	Safety Evaluation of a Medical Congress Held During the COVID-19 Pandemic-A Prospective Cohort.. 2022 , 67, 1604147	1
316	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.. 2022 , 23,	8
315	Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.. 2022 ,	1
314	Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through the Analysis of Spike Protein-Specific Core Unique Peptides.. 2022 , 10,	2
313	Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.. 2022 ,	10
312	In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.. 2022 , 20,	3
311	Genomic monitoring unveils a high prevalence of SARS-CoV-2 Omicron variant in vaccine breakthrough cases.	
310	Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. 2022 , 2, 407-418	3
309	Programmed cell death: the pathways to severe COVID-19?. 2022 , 479, 609-628	0
308	Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic?. 2022 , 10, e606	2
307	SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers.. 2022 , 10,	0
306	Mapping Data to Deep Understanding: Making the Most of the Deluge of SARS-CoV-2 Genome Sequences.. 2022 , e0003522	0
305	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2.. 2022 , 10, 801870	2

304	Impact of Vaccination, Prior Infection, and Therapy on Delta and Omicron Variants.	
303	Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters.	1
302	Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3 mRNA vaccination in health care workers and elderly subjects.. 2022,	3
301	Targeting an evolutionarily conserved "E-L-L" motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2.. 2022,	
300	Global trends in COVID-19. 2022,	1
299	Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation.. 2022 , 13, 126	1
298	A spike protein S2 antibody efficiently neutralizes the Omicron variant.. 2022,	1
297	SARS-CoV-2 Omicron variant: Immune escape and vaccine development.. 2022, 3, e126	13
296	Immune Response to SARS-CoV-2 Vaccine and Following Breakthrough Omicron Infection in an Autoimmune Patient with Hashimoto's Thyroiditis, Pernicious Anemia, and Chronic Atrophic Autoimmune Gastritis: A Case Report.. 2022, 10,	0
295	Conservation and Enhanced Binding of SARS-CoV-2 Omicron Spike Protein to Coreceptor Neuropilin-1 Predicted by Docking Analysis.. 2022, 14, 243-249	2
294	OMICRONUN TANIMI, YAZIMI VE OKUNUŞUNA DABİR DİNCELER.	
293	Peptide candidates for the development of therapeutics and vaccines against Coronavirus infection.. 2022, 13, 9435-9454	
292	Spike protein of SARS-CoV-2 variants: a brief review and practical implications.. 2022, 1	1
291	Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.. 2022,	36
290	Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine.	
289	Characteristic analysis of Omicron-included SARS-CoV-2 variants of concern.. 2022, 3, e129	0
288	Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.. 2022, 1	0
287	Unveiling the nature's fruit basket to computationally identify Citrus sinensis csi-mir169Bp as a probable plant miRNA against Reference and Omicron SARS-CoV-2 genome. 2022, 105502	2

286	The Crucial and Urgent Role of Family Physicians in Increasing COVID-19 Vaccinations.. 2022 , 115, 280-281	1
285	Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid.. 2022 , 144, 105367	2
284	Opioid usage and COVID-19 prognosis: A systematic review and meta-analysis.. 2022 , 56, 51-56	0
283	Long-term orientation and demographics predict the willingness to quarantine: A cross-national survey in the first round of COVID-19 lockdown.. 2022 , 192, 111589	1
282	Broad and Long-lasting Immune Response against SARS-CoV-2 Omicron and Other Variants by PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine (YS-SC2-010).	1
281	Analyzing the interaction of human ACE2 and RBD of spike protein of SARS-CoV-2 in perspective of Omicron variant.	
280	The rise and fall of SARS-CoV-2 variants and the mutational profile of Omicron.	0
279	SARS-CoV-2 Omicron Variant: Exploring Healthcare Workers' Awareness and Perception of Vaccine Effectiveness: A National Survey During the First Week of WHO Variant Alert.. 2022 , 10, 878159	2
278	Scope of SARS-CoV-2 variants, mutations, and vaccine technologies.. 2022 , 34, 34	2
277	Strain wars 3: Differences in infectivity and pathogenicity between Delta and Omicron strains of SARS-CoV-2 can be explained by thermodynamic and kinetic parameters of binding and growth.. 2022 , 100217	3
276	A Short Overview: Marine Resources as Potential Interventions for the Omicron SARS-CoV-2 Variant. 2022 , 2, 501-512	
275	A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.	0
274	Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study.	1
273	Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection.. 2022 , 15, 1871-1887	5
272	Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination.. 2022 ,	0
271	How Do Point Mutations Enhancing the Basic Character of the RBDs of SARS-CoV-2 Variants Affect Their Transmissibility and Infectivity Capacities?. 2022 , 14,	2
270	New Variants in SARS-CoV-2: What are we Learning from the Omicron Variant?. 2022 ,	0
269	Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant.. 2022 , 3840-3849	13

268	Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies.. 2022 , 3, 12	0
267	Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.. 2022 ,	
266	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.. 2022 ,	3
265	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. 2022 , 10, 712	
264	Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan. 2022 ,	
263	Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study.	1
262	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies.. 2022 , e2359	3
261	Risk Factors of Symptomatic COVID-19 in Samtse District, Bhutan.. 2022 , 10, 857084	1
260	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines.. 2022 ,	0
259	Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing.. 2022 ,	1
258	Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch. 2022 , 2,	1
257	Emerging SARS-CoV-2 variants: why, how, and what's next?. 2022 , 100029	3
256	Outpatient treatment options to address the SARS-CoV-2 variant Omicron.. 2022 ,	1
255	[Vaccines against coronavirus disease 2019 (COVID-19) : Efficacy comparison, safety aspects, and current challenges].. 2022 , 1	
254	Face masking and COVID-19: potential effects of variolation on transmission dynamics.. 2022 , 19, 20210781	0
253	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. 2022 , 10, 755	3
252	Infectivity versus fatality of SARS-CoV-2 mutations and influenza.. 2022 ,	4
251	FedSGDCOVID: Federated SGD COVID-19 Detection under Local Differential Privacy Using Chest X-ray Images and Symptom Information. 2022 , 22, 3728	1

- 250 Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant.. **2022**, 1
- 249 A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab. **2022**, 23, 5556 0
- 248 Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies.. **2022**,
- 247 COVID-19 Worsens Chronic Lumbosacral Radicular Pain Case Series Report. **2022**, 19, 6410
- 246 Synthesis and Biochemical Evaluation of 8H-Indeno[1,2-d]thiazole Derivatives as Novel SARS-CoV-2 3CL Protease Inhibitors. **2022**, 27, 3359 1
- 245 Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. **2022**, 12, 2
- 244 Comparing the Impact of Road Networks on COVID-19 Severity between Delta and Omicron Variants: A Study Based on Greater Sydney (Australia) Suburbs. **2022**, 19, 6551 0
- 243 Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. 9, 2
- 242 Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding. **2022**, 9, 1
- 241 Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants. 0
- 240 COVID-19: the possibility, ways, mechanisms, and interruptions of mother-to-child transmission.
- 239 Recent insights into SARS-CoV-2 omicron variant. 0
- 238 Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection. **2022**, 103941
- 237 Getting by with less - how to do more with less staff post COVID. **2022**, Publish Ahead of Print,
- 236 A novel CO₂-based demand-controlled ventilation strategy to limit the spread of COVID-19 in the indoor environment. **2022**, 219, 109232 2
- 235 Effect of Omicron on the prevalence of COVID-19 in international travelers at the Mexico city international airport. December 16th, 2021 to January 31st, 2022. **2022**, 49, 102361 0
- 234 Research Progress of SARS-CoV-2 Omicron Variant. **2022**, 11, 49-60
- 233 Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak. 54, 1

232	Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. 2022 , 10, 874	2
231	Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.	7
230	The effect of strict lockdown on Omicron SARS-CoV-2 variant transmission in Shanghai.	0
229	Evolution of telemedicine in China during COVID-19 pandemic: from 2020 to 2022.	0
228	Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq.	1
227	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. 2022 , 10, 919	2
226	Effectiveness, Policy, and User Acceptance of Covid-19 Contact Tracing Applications (CTA) During the Post-COVID-19 Pandemic: An Experience and Comparative Study (Preprint).	
225	Investigating the mutations in the SARS-CoV-2 proteins among European countries.	
224	Nomogram Model for Prediction of SARS-CoV-2 Breakthrough Infection in Fujian: A Case-Control Real-World Study. 12,	0
223	Dental Care and Education Facing Highly Transmissible SARS-CoV-2 Variants: Prospective Biosafety Setting: Prospective, Single-Arm, Single-Center Study. 2022 , 19, 7693	2
222	Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. 13,	6
221	Correlation between chest CT severity scores and clinical and biochemical parameters of COVID-19 pneumonia.	2
220	OMICRON: Virology, Immunopathogenesis, and laboratory diagnosis.	3
219	Lessons from SARS-CoV-2 and its variants (Review). 2022 , 26,	0
218	Omicron variant in Mexico: the fourth COVID-19 wave. 1-6	0
217	Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review.	1
216	Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern. 13,	0
215	SARS-CoV-2 Omicron Variant Binds to Human Cells More Strongly than the Wild Type: Evidence from Molecular Dynamics Simulation.	2

214	COVID -19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain.	1
213	SARS-CoV-2: phenotype, genotype, and characterization of different variants. 2022 , 27,	2
212	SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.	0
211	Pre-Omicron vaccine breakthrough infection induces superior cross-neutralization against SARS-CoV-2 Omicron BA.1 than primo infection.	
210	Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19.	3
209	Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland. 13,	0
208	Omicron infection in children. 2022 , 35, 78	
207	Omicron Variant Behavior in a Couple: Vaccinated Versus Non-Vaccinated. 2022 , 19, 95-101	
206	Emergence of SARS-CoV-2 B.1.1.7 and the Future of Mega Sport Events: Is This the Tipping Point from Pandemic to Endemic?. 2022 , 10, 0-0	0
205	SARS-CoV-2 vaccine breakthrough by Omicron and Delta variants: comparative assessments with New York State genomic surveillance data.	0
204	Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines Effectiveness in Delta Variant Breakthrough Infections. 2022 , 14, 1385	1
203	Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children. 2022 , 7,	0
202	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. 2022 , 13, 6064-6073	2
201	Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis. 2022 , 10, 1049	0
200	Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.	0
199	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. 2022 , 23, 7675	2
198	Fast Prediction of Binding Affinities of SARS-CoV-2 Spike Protein and Its Mutants with Antibodies through Intermolecular Interaction Modeling-Based Machine Learning.	
197	SARS-Arena: Sequence and Structure-Guided Selection of Conserved Peptides from SARS-related Coronaviruses for Novel Vaccine Development. 13,	

196	Effectiveness of Granular Lockdown as an Epidemic Control Strategy in Kerala, India. 263394472211072	
195	Structural basis for the enhanced infectivity and immune evasion of Omicron subvariants.	
194	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. 2022 , 28,	0
193	Molecular imaging on ACE2-dependent transocular infection of coronavirus.	0
192	Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases. 13,	0
191	Efficient Tracing of the SARS-CoV-2 Omicron Variants in Santa Barbara County Using a Rapid Quantitative Reverse Transcription PCR Assay.	
190	Analysis of Immunization, Adverse Events, and Efficacy of a Fourth Dose of BNT162b2 Vaccine in Health Workers in Mexico, a Pilot Study. 2022 , 10, 1139	0
189	Nanobodies: COVID-19 and Future Perspectives. 2,	0
188	Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination. 2022 , 10, 1143	3
187	Strong neutralizing antibody responses to SARS-CoV-2 variants following a single vaccine dose in subjects with previous SARS-CoV-2 infection.	1
186	Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. 2022 , 11, 1778-1786	0
185	Assessment of SARS-CoV-2 Infected Patients and Their Clinical Outcomes During the Third Wave in India: A Single-Center Observational Study. 2022 ,	
184	New SARS-CoV-2 Omicron variant Clinical picture, treatment, prevention (literature review). 2022 , 21, 3228	0
183	Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants. 13,	0
182	Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.	23
181	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. 2022 , 14, 3598	2
180	Spatiotemporal analysis of the morbidity of global Omicron from November 2021 to February 2022.	0
179	Modelling the impact of Omicron and emerging variants on SARS-CoV-2 transmission and public health burden. 2022 , 2,	2

178	A Systematic Study on the Optimal Nucleotide Analogue Concentration and Rate Limiting Nucleotide of the SARS-CoV-2 RNA-Dependent RNA Polymerase. 2022 , 23, 8302	0
177	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. Volume 15, 4013-4027	0
176	Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study.	6
175	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. 13,	1
174	Effect of Delta and Omicron mutations on the RBD-SD1 domain of the Spike protein in SARS-CoV-2 and the Omicron mutations on RBD-ACE2 interface complex.	3
173	Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19. 2022 , 14, 1769	
172	Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection. 2022 ,	1
171	Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis. 10,	3
170	Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. 2022 , 3,	2
169	FIFA Arab Cup tournament with full capacity of spectators during the COVID-19 pandemic: a cross-sectional study. 1-10	1
168	Lessons learned from an outbreak of COVID-19 in the head and neck surgery ward of a Japanese cancer center during the sixth wave by Omicron. 2022 ,	0
167	Update on the omicron sub-variants BA.4 and BA.5.	2
166	Determining SARS-CoV-2 non-infectivity state: A brief overview. 10,	
165	Molecular dynamic simulation suggests stronger interaction of Omicron-spike with ACE2 than wild but weaker than Delta SARS-CoV-2 can be blocked by engineered S1-RBD fraction.	1
164	Identification of Potential ACE2-Derived Peptide Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational Approaches. 2022 , 13, 7420-7428	1
163	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. 2022 , 23, 9297	1
162	Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques. 13,	
161	SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. 10,	

160	Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China. 2022 ,	1
159	Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study. 13,	1
158	Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period. 13,	0
157	A comprehensive modelling approach to estimate the transmissibility of coronavirus and its variants from infected subjects in indoor environments. 2022 , 12,	0
156	The relationship between knowledge about the pandemic and willingness to get vaccinated against SARS-CoV-2 in medical students in Poland: A cross-sectional survey. 10,	0
155	Vaccination in patients with kidney failure: lessons from COVID-19.	2
154	Complex Temporal behavior Modeling for Pandemic Spread: Not a Simple Delayed Response!.	
153	SARS-CoV-2 and COVID-19: A Narrative Review. 79,	1
152	The importance of booster vaccination in the context of Omicron wave. 13,	1
151	Prediction of COVID-19 infection spread through agent-based simulation. 2022 ,	0
150	Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain. 2022 , 149, 106035	0
149	SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA. 2022 , 28,	1
148	Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies [Correspondence. 2022 , 106, 106903	2
147	Omicron variant: Current insights and future directions. 2022 , 265, 127204	6
146	Nonlinear optimal control strategies for a mathematical model of COVID-19 and influenza co-infection. 2022 , 607, 128173	3
145	A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. 2022 , 19, 10361-10373	1
144	Will New Variants Emerge after Delta and Omicron?. 2022 , 13, 1317	0
143	Omicron Coronavirus Variant: pH-Dependent Electrostatic Potentials and Energy of Association of S-Protein to ACE2 Receptor.	0

- 142 Global Coronavirus Pandemic Crisis. **2022**, 89-128 ○
- 141 Effectiveness, Policy, and User Acceptance of Covid-19 Contact Tracing Applications (CTAs) During the Post-COVID-19 Pandemic: An Experience and Comparative Study (Preprint). ○
- 140 The Effect of Strict Lockdown on Omicron SARS-CoV-2 Variant Transmission in Shanghai. **2022**, 10, 1392 ○
- 139 Hom-Complex-Based Machine Learning (HCML) for the Prediction of Protein-Protein Binding Affinity Changes upon Mutation. **2022**, 62, 3961-3969 ○
- 138 COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region Experience. **2022**, 10, 1362 1
- 137 Synthesis and In Silico Docking Study towards M-Pro of Novel Heterocyclic Compounds Derived from Pyrazolopyrimidinone as Putative SARS-CoV-2 Inhibitors. **2022**, 27, 5303 ○
- 136 Age and Sex Differences Among Mildly Symptomatic and Asymptomatic Patients with Omicron Infection in 2022 in Shanghai, China. Volume 15, 1909-1919 ○
- 135 Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron. 9, 1 1
- 134 Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2. 1 1
- 133 Characterization of SARS-CoV-2 Omicron variant shedding and predictors of viral culture positivity on vaccinated healthcare workers with mild COVID-19. ○
- 132 Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19. **2022**, 22, 1 1
- 131 Molecular Mechanism of the Non-Covalent Orally Targeted SARS-CoV-2 Mpro Inhibitor S-217622 and Computational Assessment of Its Effectiveness against Mainstream Variants. **2022**, 13, 8893-8901 1 1
- 130 Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. ard-2022-222904 ○
- 129 Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein. 13, ○
- 128 Computation of the Binding Energies between Human ACE2 and Spike RBDs of the Original Strain, Delta and Omicron Variants of the SARS-CoV-2: A DFT Simulation Approach. 2200337 ○
- 127 Epidemiology and course of infectious diseases during the COVID-19 pandemic. Report 1. HIV infection, hepatitis c and tuberculosis. **2022**, 12, 639-650 1 1
- 126 The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron. **2022**, 14, 2009 ○
- 125 Methamphetamine use and adoption of preventive behaviors early in the COVID-19 pandemic among men who have sex with men in Los Angeles, California. **2022**, 100097 ○

124	SARS-CoV-2 Omicron and its current known unknowns: A narrative review.	3
123	Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex. 2022 , 23, 10091	0
122	Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.	1
121	Variant-specific SARS-CoV-2 shedding rates in wastewater. 2022 , 159165	0
120	DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. 2022 , 13,	1
119	A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. 2022 , 111554	1
118	Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.	0
117	Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. 2022 , 150, 106129	2
116	Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic. 2022 , 16, 117863022211293	3
115	Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants.	8
114	Prediction of global omicron pandemic using ARIMA, MLR, and Prophet models. 2022 , 12,	1
113	SARS-CoV-2 variants of concern: a review.	0
112	Vaccine- and BTI-elicited pre-Omicron immunity more effectively neutralizes Omicron sublineages BA.1, BA.2, BA.4 and BA.5 than pre-Omicron infection alone.	0
111	Evolutionary Pattern Comparisons of the SARS-CoV-2 Delta Variant in Countries/Regions with High and Low Vaccine Coverage. 2022 , 14, 2296	1
110	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. 13,	0
109	Targeting an evolutionarily conserved E-L-L motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2. 2022 , 1,	0
108	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections.	0
107	A comparative study of spike protein of SARS-CoV-2 and its variant Omicron (B.1.1.529) on some immune characteristics. 2022 , 12,	1

106	Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants. 2022 , 106262	1
105	Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India. 9,	0
104	Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV). 2022 , 12, 950	0
103	Effect of Vaccination Time Intervals on SARS-COV-2 Omicron Variant Strain Infection in Guangzhou: A Real-World Matched Case-Control Study. 2022 , 10, 1855	0
102	D3AI-Spike: A deep learning platform for predicting binding affinity between SARS-CoV-2 spike receptor binding domain with multiple amino acid mutations and human angiotensin-converting enzyme 2. 2022 , 151, 106212	0
101	Efficacy and safety of Reyaning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial. 2023 , 108, 154514	0
100	Biomolecular Topology: Modelling and Analysis. 2022 , 38, 1901-1938	0
99	SARS-CoV-2 variants, immune escape, COVID-19 vaccine, and therapeutic strategies.	0
98	Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. 2022 ,	0
97	An intranasal self-amplifying RNA SARS-CoV-2 vaccine produces durable respiratory and systemic immunity.	0
96	Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. 1-16	2
95	Neighborhood social cohesion is associated with the willingness toward the booster dose of COVID-19 vaccines among the Chinese older population.	1
94	Transcriptomic study reveals lncRNA-mediated downregulation of innate immune and inflammatory response in the SARS-CoV-2 vaccination breakthrough infections. 13,	0
93	Strong neutralizing antibody responses to SARS-CoV-2 variants following a single vaccine dose in subjects with previous SARS-CoV-2 infection.	0
92	Global Emerging Omicron Variant of SARS-CoV-2: Impacts, Challenges and Strategies. 2022 ,	12
91	Mutations in Spike Gene of SARS-CoV-2 that Are Associated with a Higher Viral Load: A Clinical Case Study. 2022 , 11, 474-486	0
90	Severe acute respiratory syndrome coronavirus 2 Omicron variant and psychological distress among frontline nurses in a major COVID-19 center: Implications for supporting psychological well-being. 2022 , 0	0
89	Association of anosmia and neutralizing antibody production in adolescents with SARS-CoV-2. 2023 , 164, 111403	0

88	Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis. 2023 , 28, 101605	1
87	Airport terminal passenger forecast under the impact of COVID-19 outbreaks: A case study from China. 2023 , 65, 105740	0
86	The risk of SARS-CoV-2 Omicron variant emergence in low and middle-income countries (LMICs). 2023 , 42, 100660	0
85	Comparison of clinical characteristics of wild-type SARS-CoV-2 and Omicron. 2022 , 68, 1476-1480	2
84	Time-series comparison of COVID-19 case fatality rates across 21 countries with adjustment for multiple covariates.	0
83	Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review. 2022 , 58, 1733	0
82	Characteristics of the severe acute respiratory syndrome coronavirus 2 omicron BA.2 subvariant in Jilin, China from March to May 2022. 2022 ,	0
81	Predicting Oxygen Utilization & Nurse Staffing Needs For COVID-19. 2022 ,	0
80	Evaluation and comparison of the sensitivity of three commercial RT-qPCR kits used for the detection of SARS-CoV-2 in Santiago, Chile. 10,	0
79	Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. 2022 , 23, 14341	0
78	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. 2022 , 12, 1742	1
77	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. 13,	0
76	A Comparison Study of the Detection Limit of Omicron SARS-CoV-2 Nucleocapsid by Various Rapid Antigen Tests. 2022 , 12, 1083	0
75	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?.	0
74	Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality.	0
73	In silico study of SARS-CoV-2 Spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron sub-variants.	0
72	Nucleic acid testing of SARS-CoV-2: A review of current methods, challenges, and prospects. 13,	0
71	Anti-Arbovirus Antibodies Cross-React With Severe Acute Respiratory Syndrome Coronavirus 2. 2022 , 10,	0

70	Impact of BA.1, BA.2, and BA.4/BA.5 Omicron Mutations on Therapeutic Monoclonal Antibodies.	2
69	Social Network Analysis of COVID-19 Research and the Changing International Collaboration Structure.	0
68	Digital PCR discriminates between SARS-CoV-2 Omicron variants and immune escape mutations.	0
67	Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations. 2023 , 43, 290-294	0
66	Neutralization of SARS-CoV-2 omicron after BBIBP-CorV and ZF2001 booster vaccination. 2022 , 102531	0
65	A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility. 13,	1
64	Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. 2022 , 10, 2111	0
63	Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). 13,	1
62	Hybrid immunity and protection against infection during the Omicron wave in Malta. 1-22	0
61	Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic. 2022 , 7,	1
60	Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.	0
59	L-shape distribution of the relative substitution rate (c/μ) observed for SARS-COV-2 genome, inconsistent with the selectionist theory, the neutral theory and the nearly neutral theory but a near-neutral balanced selection theory: implication on neutralist-selectionist debate.	0
58	Genomic characterization and molecular evolution of SARS-CoV-2 in Rio Grande do Sul State, Brazil.	0
57	Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management. 2023 , 11, 160	2
56	Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice. 2023 ,	1
55	Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose. Publish Ahead of Print,	0
54	Hand Hygiene, Face Mask Use, and Associated Factors during the COVID-19 Pandemic among the Students of Mongar Higher Secondary School, Bhutan: A Cross-Sectional Study. 2023 , 20, 1058	1
53	Evolutionary rate of SARS-CoV-2 increases during zoonotic infection of farmed mink.	1

52	Detection of hospital environmental contamination during SARS-CoV-2 Omicron predominance using a highly sensitive air sampling device. 10,	0
51	L-shaped distribution of the relative substitution rate (c/π) observed for SARS-COV-2's genome, inconsistent with the selectionist theory, the neutral theory and the nearly neutral theory but a near-neutral balanced selection theory: Implication on Neutralist-selectionist debate. 2023 , 153, 106522	0
50	Omicron. 2023 , 367-413	0
49	Symptom profiles of community cases infected by Influenza, RSV, rhinovirus, seasonal coronavirus, and SARS-CoV-2 variants of concern.	0
48	SARS-CoV-2 emerging Omicron subvariants with a special focus on BF.7 and XBB.1.5 recently posing fears of rising cases amid ongoing COVID-19 pandemic. 2022 , 10, 1215-1221	1
47	The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants. 2022 , 12,	0
46	Genomic epidemiology of SARS- CoV-2 Omicron variants in the Republic of Korea. 2022 , 12,	0
45	Emerging Dominant SARS-CoV-2 Variants. 2023 , 63, 335-342	5
44	Depression, Anxiety, Stress, and Suicidality Levels in Young Adults Increased Two Years into the COVID-19 Pandemic. 2023 , 20, 339	0
43	Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity. 2023 , 15, 309	0
42	The Relationship between the Transmission of Different SARS-CoV-2 Strains and Air Quality: A Case Study in China. 2023 , 20, 1943	0
41	SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. 2023 , 13, 559	1
40	How public health authorities can use pathogen genomics in health protection practice: a consensus-building Delphi study conducted in the United Kingdom. 2023 , 9,	0
39	Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation. 2023 , 12, 17	0
38	SARS-CoV -2 neutralizing antibody epitopes are overlapping and highly mutated which raises the chances of escape variants and requires development of broadly reactive vaccines.	0
37	Clinical Outcomes and Phylogenetic analysis in Reflection with Three Predominant Clades of SARS-CoV -2 Variants.	0
36	The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs. 2023 , 225, 115612	0
35	Genomic characterization and molecular evolution of SARS-CoV-2 in Rio Grande do Sul State, Brazil. 2023 , 582, 1-11	0

- 34 Antiviral PROTACs: Opportunity borne with challenge. **2023**, 2, 100092 ○
- 33 Is BF.7 more infectious than other Omicron subtypes: Insights from structural and simulation studies of BF.7 spike RBD variant. **2023**, 238, 124154 ○
- 32 Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China. **2023**, 19, ○
- 31 Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern. 13, ○
- 30 Chest computed tomography findings of the Omicron variants of SARS-CoV-2 with different cycle threshold values. 11, 756-763 ○
- 29 Vaccine Hesitancy among Medical Students at a Tertiary Hospital Affiliated Medical School. **2023**, 11, 461 ○
- 28 Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. **2023**, 11, 517 ○
- 27 Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis. **2023**, 20, 3335 ○
- 26 Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract: a systematic review and meta-analysis. **2023**, 129, 228-235 ○
- 25 Neutralization Effect of Sera against Delta and Omicron in Patients Recovering from COVID-19 and Inactivated Vaccine Recipients. **2023**, 11, 471 ○
- 24 Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone. **2023**, 45, 1741-1761 ○
- 23 The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19. ○
- 22 Centrifugal microfluidic-based multiplex recombinase polymerase amplification assay for rapid detection of SARS-CoV-2. **2023**, 26, 106245 ○
- 21 Children's Symptoms with a Febrile Illness and a Positive or Negative Test of SARS-CoV-2 during the Omicron Wave. **2023**, 10, 419 ○
- 20 SARS-CoV-2 Omicron variant of concern in the Seychelles: Introduction and spread. 8, 105 ○
- 19 Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay. **2023**, 13, 889 ○
- 18 Twitter-Based Sentiment Analysis and Topic Modeling of Social Media Posts using Natural Language Processing, to Understand People's Perspectives Regarding COVID-19 Omicron Subvariants XBB.1.5 and BF.7. **2023**, 17, 515-523 ○
- 17 Physical Impact of SARS-CoV-2 Infection in a Population of Italian Healthcare Workers. **2023**, 20, 4506 ○

- 16 Genomic monitoring unveils a high prevalence of severe acute respiratory syndrome coronavirus 2 Omicron variant in vaccine breakthrough cases in Bahia, Brazil. **2023**, 69, 257-261 ○
- 15 Artificial Intelligence: A Next-Level Approach in Confronting the COVID-19 Pandemic. **2023**, 11, 854 ○
- 14 Applications of Artificial Intelligence and Big Data for Covid-19 Pandemic: A Review. **2022**, ○
- 13 Conformational Behavior of SARS-Cov-2 Spike Protein Variants: Evolutionary Jumps in Sequence Reverberate in Structural Dynamic Differences. **2023**, 19, 2120-2134 ○
- 12 Hematological features of patients with type 2 diabetes depending on the variant of SARS-COV-2. **2023**, 69, 35-42 ○
- 11 Prevalence of taste and smell dysfunction in mild and asymptomatic COVID-19 patients during Omicron prevalent period in Shanghai, China: a cross-sectional survey study. **2023**, 13, e067065 ○
- 10 CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases. 10, ○
- 9 Increased SARS-CoV-2 seroprevalence and spread of infection without awareness among healthcare workers through 2020-2022 in a Japanese medical center. **2023**, 13, ○
- 8 Hidroxicloroquina para Pacientes com COVID-19 nã Hospitalizados: Uma Revisã Sistemãica e Metanãlise de Ensaios Clãnicos Randomizados. **2023**, 120, ○
- 7 Clinical Profile and Risk Factors for Severe COVID-19 in Hospitalized Patients from Rio de Janeiro, Brazil: Comparison between the First and Second Pandemic Waves. **2023**, 12, 2568 ○
- 6 Policy Disparities Between Singapore and Israel in Response to the First Omicron Wave. Volume 16, 489-502 ○
- 5 Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease. **2023**, 207, 106267 ○
- 4 2022? ?????????? ?? ?????? ??????????-19 ?? ???. **2023**, 16, 381-393 ○
- 3 Effects of Chinese provincial CDCs WeChat official account article features on user engagement during the COVID-19 pandemic. 13, ○
- 2 Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. **2023**, 100613 ○
- 1 Lessons drawn from Shanghai for controlling highly transmissible SARS-CoV-2 variants: insights from a modelling study. **2023**, 23, ○